Entering text into the input field will update the search result below

ZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper On Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

ZIOPHARM Oncology, Inc. (ZIOP) Q4 2017 Earnings Conference Call March 1, 2018 4:30 PM ET


David Connolly - VP, Corporate Communications & IR

Laurence Cooper - CEO

David Mauney - Executive Vice President and Chief Business Officer


Bin Lu - Raymond James

Keith Markey - Griffin Securities

Swayampakula Ramakanth - H.C. Wainwright & Co.

Nicholas Abbott - Wells Fargo Securities



Good afternoon, ladies and gentlemen, and welcome to the ZIOPHARM Fourth Quarter and Year-end Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Dave Connolly, Vice President of Corporate Communications and Investor Relations.

David Connolly

Thank you. Earlier today, we released our financial results for the fourth quarter and year-end 2017 with a press release available on our website, ziopharm.com. During today's call, representatives of the company will make a number of statements that are forward-looking, including statements regarding the potential of therapeutic candidates in our development pipeline, forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control including the risks and uncertainties described in our SEC filings. Results may differ materially from those projected on today's call and we undertake no obligation to publicly update any forward-looking statements.

We'll review our clinical development programs and financials and take a few questions from covering analysts today.

And now I'll turn the call over to Dr. Laurence Cooper, CEO of ZIOPHARM Oncology, who'll be in today's call.

Laurence Cooper

Great. Good afternoon, everybody. Thank you, David and we're on Slide 3. With me here in Boston for the call is Dr. David Mooney, Executive Vice President, Chief Business Officer and also our interim Chief Operating Officer; and on the phone and from the road is Dr. Francois Lebel, the Executive Vice President of the

Recommended For You

Comments (2)

Short squeeze
Listened to the conference call and am very impressed with the pipeline progress, especially the ability to apply non-viral DNA edits to patient's own T-cells at the point of care and all within a two day time frame (the Sleeping Beauty technology). That's Huge.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.